Publisher
Center for Scientific Research and Development of Education
Reference11 articles.
1. Butler J, Shah SJ, Petrie MC, Bourlag BE, Abidstrom SZ, Davies MJ, et al. Semaglutide versus placebo in people with obesity.-related heart failure with preserved ejection fraction: A pooled analysis of STEP- HFpEF and STEP- HFpEF DM trials. Lancet 29024; 403: 1835-48.
2. Maron MS, Masri A, Nassif ME, Barriales –Villa R, Arad M, Cardim N, et al. for the SEQUOIA _ HCM investigators. Aficamten for symptomatic obstructive cardiomyopathy. N Engl J Med 2024; 390: 1849-61
3. Li X, Ge Z, Kan J, Anjium M, Xie P, Chen X, et al. Intravascular ultrasound –guided versusu angiography guided percutaneous coronary intervention in acute coronary sydnroem (IVUS_ACS): a two-stage, multicenter, randomized trial. Lancet 29024; 403: 1855-65
4. Park SJ, Ahn JM, Kang DY, Yun SC, Ahn K, Kim WJ. Preventive percutaneous intervention versus optimal medical therapy alone for the treatment of vulnerable atherosclerotic coronary plaques (PREVENT ): a multicenter, open-lable, randomized controlled trial. Lancet 2024; 403: 1858-65.
5. Ge Z, Kan J, Gao X, Raza A, Zhang JJ, Mohydin BS, Rza A, et al. Ticagrelor alone versus ticagrelor plus aspirin from 1 month to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE DAPAT): a randomized, placebo-controlled , double-blind clinical trial. Lancet 2024; 403: 1866-78.